Annual SGA
$96.82 M
+$5.89 M+6.48%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual SGA is $96.82 million, with the most recent change of +$5.89 million (+6.48%) on September 30, 2024.
- During the last 3 years, ARWR annual SGA has risen by +$15.84 million (+19.56%).
- ARWR annual SGA is now -22.19% below its all-time high of $124.43 million, reached on September 30, 2022.
Performance
ARWR SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$25.79 M
+$2.59 M+11.16%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly SGA is $25.79 million, with the most recent change of +$2.59 million (+11.16%) on September 30, 2024.
- Over the past year, ARWR quarterly SGA has increased by +$1.14 million (+4.63%).
- ARWR quarterly SGA is now -32.65% below its all-time high of $38.29 million, reached on September 30, 2021.
Performance
ARWR Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$5.52 B
-$599.49 M-12.17%
September 30, 2024
Summary
- As of February 7, 2025, ARWR TTM SGA is -$5.52 billion, with the most recent change of -$599.49 million (-12.17%) on September 30, 2024.
- Over the past year, ARWR TTM SGA has dropped by -$5.62 billion (-5891.70%).
- ARWR TTM SGA is now -277649.18% below its all-time high of -$1.99 million.
Performance
ARWR TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
ARWR Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.5% | +4.6% | -5891.7% |
| 3 y3 years | +19.6% | -32.6% | -6920.8% |
| 5 y5 years | +264.6% | -32.6% | -6920.8% |
ARWR Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -22.2% | +19.6% | -23.9% | +25.3% | -122.3% | at low |
| 5 y | 5-year | -22.2% | +264.6% | -32.6% | +198.2% | -222.3% | at low |
| alltime | all time | -22.2% | >+9999.0% | -32.6% | +702.4% | <-9999.0% | at low |
Arrowhead Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | $96.82 M(+6.5%) | $25.79 M(+11.2%) | $96.82 M(+1.7%) |
| Jun 2024 | - | $23.20 M(-5.9%) | $95.20 M(-0.2%) |
| Mar 2024 | - | $24.64 M(+6.3%) | $95.37 M(+2.0%) |
| Dec 2023 | - | $23.19 M(-4.0%) | $93.54 M(+2.9%) |
| Sep 2023 | $90.93 M(-26.9%) | $24.17 M(+3.4%) | $90.93 M(-9.1%) |
| Jun 2023 | - | $23.37 M(+2.4%) | $100.00 M(-8.6%) |
| Mar 2023 | - | $22.82 M(+10.9%) | $109.37 M(-9.2%) |
| Dec 2022 | - | $20.58 M(-38.1%) | $120.42 M(-3.2%) |
| Sep 2022 | $124.43 M(+53.7%) | $33.24 M(+1.5%) | $124.43 M(-3.9%) |
| Jun 2022 | - | $32.74 M(-3.3%) | $129.48 M(+13.0%) |
| Mar 2022 | - | $33.86 M(+37.7%) | $114.60 M(+18.2%) |
| Dec 2021 | - | $24.59 M(-35.8%) | $96.93 M(+19.7%) |
| Sep 2021 | $80.98 M(+54.9%) | $38.29 M(+114.4%) | $80.98 M(+41.0%) |
| Jun 2021 | - | $17.86 M(+10.3%) | $57.42 M(+14.5%) |
| Mar 2021 | - | $16.19 M(+87.2%) | $50.16 M(+0.0%) |
| Dec 2020 | - | $8.65 M(-41.3%) | $50.14 M(-4.1%) |
| Sep 2020 | $52.28 M(+96.9%) | $14.72 M(+39.0%) | $52.28 M(+9.3%) |
| Jun 2020 | - | $10.60 M(-34.5%) | $47.82 M(+13.8%) |
| Mar 2020 | - | $16.17 M(+49.9%) | $42.04 M(+34.7%) |
| Dec 2019 | - | $10.79 M(+5.0%) | $31.20 M(+17.5%) |
| Sep 2019 | $26.56 M(+39.0%) | $10.27 M(+113.5%) | $26.55 M(+16.9%) |
| Jun 2019 | - | $4.81 M(-9.9%) | $22.71 M(+1.0%) |
| Mar 2019 | - | $5.34 M(-13.0%) | $22.50 M(+8.0%) |
| Dec 2018 | - | $6.13 M(-4.6%) | $20.83 M(+9.1%) |
| Sep 2018 | $19.11 M(+9.2%) | $6.43 M(+40.0%) | $19.09 M(+5.6%) |
| Jun 2018 | - | $4.59 M(+25.1%) | $18.09 M(+3.9%) |
| Mar 2018 | - | $3.67 M(-16.4%) | $17.41 M(-0.0%) |
| Dec 2017 | - | $4.40 M(-18.9%) | $17.42 M(-19.3%) |
| Sep 2017 | $17.50 M(-25.8%) | $5.42 M(+38.3%) | $21.57 M(+81.7%) |
| Jun 2017 | - | $3.92 M(+6.6%) | $11.87 M(-30.5%) |
| Mar 2017 | - | $3.68 M(-57.0%) | $17.09 M(-28.5%) |
| Dec 2016 | - | $8.55 M(-299.9%) | $23.90 M(+1.3%) |
| Sep 2016 | $23.59 M(-32.0%) | -$4.28 M(-146.8%) | $23.59 M(-41.0%) |
| Jun 2016 | - | $9.14 M(-12.8%) | $40.01 M(+3.2%) |
| Mar 2016 | - | $10.48 M(+27.0%) | $38.76 M(+8.5%) |
| Dec 2015 | - | $8.25 M(-32.0%) | $35.72 M(+2.9%) |
| Sep 2015 | $34.72 M(+42.2%) | $12.14 M(+53.9%) | $34.72 M(+9.4%) |
| Jun 2015 | - | $7.89 M(+5.9%) | $31.74 M(+6.0%) |
| Mar 2015 | - | $7.44 M(+2.6%) | $29.93 M(+6.4%) |
| Dec 2014 | - | $7.25 M(-20.8%) | $28.13 M(+15.3%) |
| Sep 2014 | $24.42 M(+108.8%) | $9.16 M(+50.8%) | $24.40 M(+34.0%) |
| Jun 2014 | - | $6.08 M(+7.6%) | $18.21 M(+21.0%) |
| Mar 2014 | - | $5.64 M(+60.5%) | $15.05 M(+22.7%) |
| Dec 2013 | - | $3.52 M(+18.2%) | $12.27 M(+4.9%) |
| Sep 2013 | $11.69 M(-17.0%) | $2.97 M(+2.1%) | $11.69 M(+0.4%) |
| Jun 2013 | - | $2.92 M(+1.9%) | $11.65 M(-16.4%) |
| Mar 2013 | - | $2.86 M(-2.8%) | $13.94 M(-1.8%) |
| Dec 2012 | - | $2.94 M(+0.4%) | $14.20 M(+0.7%) |
| Sep 2012 | $14.10 M | $2.93 M(-43.7%) | $14.10 M(+4.4%) |
| Jun 2012 | - | $5.21 M(+67.1%) | $13.50 M(+40.2%) |
| Mar 2012 | - | $3.12 M(+9.8%) | $9.63 M(+18.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | $2.84 M(+21.4%) | $8.12 M(+23.2%) |
| Sep 2011 | $6.58 M(+80.9%) | $2.34 M(+74.7%) | $6.59 M(+49.9%) |
| Jun 2011 | - | $1.34 M(-16.5%) | $4.39 M(+3.1%) |
| Mar 2011 | - | $1.60 M(+22.4%) | $4.26 M(+13.0%) |
| Dec 2010 | - | $1.31 M(+813.9%) | $3.77 M(-14.5%) |
| Sep 2010 | $3.64 M(-74.1%) | $143.30 K(-88.1%) | $4.41 M(-35.8%) |
| Jun 2010 | - | $1.21 M(+8.6%) | $6.88 M(-14.0%) |
| Mar 2010 | - | $1.11 M(-43.0%) | $8.00 M(-25.2%) |
| Dec 2009 | - | $1.95 M(-25.1%) | $10.69 M(-23.9%) |
| Sep 2009 | $14.04 M(-40.9%) | $2.61 M(+11.9%) | $14.04 M(-22.4%) |
| Jun 2009 | - | $2.33 M(-38.8%) | $18.09 M(-18.8%) |
| Mar 2009 | - | $3.80 M(-28.2%) | $22.28 M(-7.5%) |
| Dec 2008 | - | $5.30 M(-20.3%) | $24.09 M(+0.5%) |
| Sep 2008 | $23.75 M(+39.0%) | $6.65 M(+2.0%) | $23.98 M(+5.9%) |
| Jun 2008 | - | $6.52 M(+16.1%) | $22.65 M(+7.2%) |
| Mar 2008 | - | $5.61 M(+8.1%) | $21.14 M(+9.0%) |
| Dec 2007 | - | $5.19 M(-2.5%) | $19.39 M(+13.5%) |
| Sep 2007 | $17.09 M(+46.7%) | $5.33 M(+6.4%) | $17.09 M(+19.4%) |
| Jun 2007 | - | $5.00 M(+29.5%) | $14.31 M(+10.5%) |
| Mar 2007 | - | $3.86 M(+33.5%) | $12.96 M(+8.8%) |
| Dec 2006 | - | $2.89 M(+13.3%) | $11.91 M(+10.9%) |
| Sep 2006 | $11.65 M(+86.5%) | $2.55 M(-30.0%) | $10.74 M(+3.8%) |
| Jun 2006 | - | $3.65 M(+29.7%) | $10.34 M(+24.2%) |
| Mar 2006 | - | $2.81 M(+63.3%) | $8.33 M(+22.1%) |
| Dec 2005 | - | $1.72 M(-20.2%) | $6.82 M(+9.2%) |
| Sep 2005 | $6.25 M(+198.4%) | $2.16 M(+32.2%) | $6.25 M(+17.7%) |
| Jun 2005 | - | $1.63 M(+25.1%) | $5.31 M(+30.2%) |
| Mar 2005 | - | $1.31 M(+13.6%) | $4.08 M(+29.0%) |
| Dec 2004 | - | $1.15 M(-5.8%) | $3.16 M(+51.0%) |
| Sep 2004 | $2.09 M(+2198.4%) | $1.22 M(+204.3%) | $2.09 M(+136.7%) |
| Jun 2004 | - | $401.00 K(+2.9%) | $884.30 K(+77.4%) |
| Mar 2004 | - | $389.80 K(+376.5%) | $498.60 K(+258.4%) |
| Dec 2003 | - | $81.80 K(+599.1%) | $139.10 K(+52.7%) |
| Sep 2003 | $91.10 K(-36.6%) | $11.70 K(-23.5%) | $91.10 K(-26.6%) |
| Jun 2003 | - | $15.30 K(-49.5%) | $124.10 K(-21.4%) |
| Mar 2003 | - | $30.30 K(-10.4%) | $157.90 K(+4.8%) |
| Dec 2002 | - | $33.80 K(-24.4%) | $150.60 K(+4.7%) |
| Sep 2002 | $143.80 K(+31.6%) | $44.70 K(-9.0%) | $143.80 K(+16.2%) |
| Jun 2002 | - | $49.10 K(+113.5%) | $123.70 K(+32.6%) |
| Mar 2002 | - | $23.00 K(-14.8%) | $93.30 K(-2.7%) |
| Dec 2001 | - | $27.00 K(+9.8%) | $95.90 K(-12.3%) |
| Sep 2001 | $109.30 K(-17.2%) | $24.60 K(+31.6%) | $109.30 K(-8.5%) |
| Jun 2001 | - | $18.70 K(-27.0%) | $119.40 K(-7.1%) |
| Mar 2001 | - | $25.60 K(-36.6%) | $128.50 K(-4.7%) |
| Dec 2000 | - | $40.40 K(+16.4%) | $134.80 K(+2.0%) |
| Sep 2000 | $132.00 K(+46.0%) | $34.70 K(+24.8%) | $132.10 K(+35.6%) |
| Jun 2000 | - | $27.80 K(-12.9%) | $97.40 K(+39.9%) |
| Mar 2000 | - | $31.90 K(-15.4%) | $69.60 K(+84.6%) |
| Dec 1999 | - | $37.70 K | $37.70 K |
| Sep 1999 | $90.40 K(+15.9%) | - | - |
| Sep 1998 | $78.00 K(-13.1%) | - | - |
| Sep 1997 | $89.80 K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual SGA?
- What is the all time high annual SGA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual SGA year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly SGA year-on-year change?
- What is Arrowhead Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM SGA year-on-year change?
What is Arrowhead Pharmaceuticals annual SGA?
The current annual SGA of ARWR is $96.82 M
What is the all time high annual SGA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual SGA is $124.43 M
What is Arrowhead Pharmaceuticals annual SGA year-on-year change?
Over the past year, ARWR annual SGA has changed by +$5.89 M (+6.48%)
What is Arrowhead Pharmaceuticals quarterly SGA?
The current quarterly SGA of ARWR is $25.79 M
What is the all time high quarterly SGA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly SGA is $38.29 M
What is Arrowhead Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, ARWR quarterly SGA has changed by +$1.14 M (+4.63%)
What is Arrowhead Pharmaceuticals TTM SGA?
The current TTM SGA of ARWR is -$5.52 B
What is the all time high TTM SGA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM SGA is -$1.99 M
What is Arrowhead Pharmaceuticals TTM SGA year-on-year change?
Over the past year, ARWR TTM SGA has changed by -$5.62 B (-5891.70%)